Lightbits Labs Named Storage Company of the Year and Receives Storage Hardware Award for SuperSSD NVMe/TCP at SDC Awards
At the recent SDC Awards gala here, Lightbits Labs took home two prestigious awards, Storage Company of the Year and Hardware Innovation of the Year. Lightbits received the nod for storage company of the year for its software defined storage (SDS) solution that brings hyperscale efficiency to on-premise cloud infrastructure with low-latency composable storage. Lightbits’ SuperSSD NVMe/TCP Storage Server , the World’s First Ultra-High Capacity, High Performance SSD Storage Appliance solution was selected as the most innovative hardware solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005290/en/
Lightbits Labs takes home storage company of the year and wins storage hardware award for SuperSSD NVMe/TCP at the SDC Awards. Posing with the awards from left to right are: Kam Eshghi, Chief Strategy Officer, Shirley Kirzner, Eran Kirzner, Chief Executive Officer and Co-Founder, George Agasandian, Director of Solutions Engineering and Co-Founder, Ofir Efrati, VP of Engineering and Co-Founder, Shaul Galia, Chief Operations Officer, and Miki Avni, Chief Financial Officer. (Photo; Business Wire)
The SDC (Storage, Digitalization + Cloud) Awards, now in their 10th year, recognize and reward success in the products and services that are foundational to digital transformation. Lightbits received the honor for how the company is reimagining hyperscale storage for next-generation applications.
Co-founded by veteran Israeli entrepreneur and founder of Annapurna Avigdor Willenz, Lightbits introduced three groundbreaking technologies in its first year out of stealth mode: LightOS, LightField, and SuperSSD. The company was cited for its leadership in delivering software defined solution that runs on commodity hardware to disaggregate storage and compute over standard networks, allowing them to scale independently (increasing flexibility & efficiency) and maximizing resource utilization (lowering TCO) while delivering performance that is similar to direct-attached SSDs. Lightbits pioneered NVMe/TCP so its solution is easy to deploy at scale.
“Being recognized by our peers and voters from around the globe for this award highlights the increasingly important role of practical, smart and forward-thinking storage solutions for true digital transformation,” said Eran Kirzner, co-founder and CEO at Lightbits Labs. “Companies are responsible for vast amounts of data through both public and private clouds, and the volume of data continues to grow exponentially. We’re proud that our solutions are being recognized for their transformational role in addressing the data storage challenges that are so prevalent in enterprises today.”
In March 2019, Lightbits introduced its groundbreaking LightOS and LightField. The LightOS software and LightField storage acceleration card provide a high-performance, end-to-end disaggregation solution that can scale without requiring any changes to data center clients or network infrastructure. They were the industry’s first NVMe/TCP solutions to provide a Global Flash Translation Layer (GFTL) running over high-performance standard networks. The solutions allow private clouds and software-as-a-service (SaaS) providers to capitalize on the application performance of using local NVMe SSDs with the simplicity and efficiency of hyperscale solutions.
As trailblazers of a new storage paradigm, Lightbits’ solutions are successfully being used in industry-leading cloud data centers around the globe. The company is gaining industry recognition for its ground-breaking solutions and has received three industry awards over the past six months.
Lightbits Labs Resources
For additional information, contact info@lightibtslabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz, Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht, (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005290/en/
Contact information
Alan Ryan/Marianne Dempsey
alanryan@rainierco.com/ mdempsey@rainierco.com
508-475-0025, ext. 116 or 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom